5 Best Stocks to Buy for Sinful Gains This May

The idea of investing in “vice stocks,” which are involved in activities considered immoral, is often off-putting. But, products or services in this space are relatively inelastic, and business is recession-proof. The very nature of their business ensures a stable stream of consumers, irrespective of market conditions, which eventually leads to higher margins and solid profits.

And we cannot ignore the current stock market turbulence and specter of slower economic growth, which are already unnerving investors. U.S.-China trade tensions are currently triggering global growth fears and compelling investors to stay away from riskier assets like equities.

The International Monetary Fund is also raising red flags. The international agency projected a slowdown in global growth for this year, thanks to macroeconomic stress in Argentina and Turkey and disruptions in Germany’s auto sector, to name a few. By the way, from Fed to ECB to Bank of Japan and Bank of England, all have shifted to an accommodative stance due to global growth concerns, which makes investing in sin stocks more desirable.

But before we zero in on stocks from this tempting space, let’s take a look at what’s in store for these companies.

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Marijuana Fever Here to Stay” data-reactid=”15″>Marijuana Fever Here to Stay

The cannabis industry is likely to create a lot of noise this year. After all, Canada has become the first major economy to legalize recreational pot, with quite a number of U.S. states giving green signal to cannabis in some capacity last year.

The U.S. Food and Drug Administration did approve its very first cannabis-derived drug, and thus marijuana became a legitimate business model last year. This year, in fact, the global consumer marijuana outlays are estimated to climb 38% to $16.9 billion, up from a projected $12.2 billion last year, $9.5 billion in 2017, and $6.9 billion in 2016, per Arcview Market Research and BDS Analytics. Additionally, compounded global annual sales growth of cannabis from 2017 to 2022 is projected at $31.3 billion.

Investment bank Cowen & Co further added that the legal weed market is expected to reach a worth of as much as $75 billion by 2030. This indicates that there are plenty of opportunities for investors to make money from both direct and subsidiary players, who won’t touch the plant but will surely benefit from this fast-growing industry.

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Booze Consumption Picks Up” data-reactid=”19″>Booze Consumption Picks Up

Last year, no doubt, was a horrible year for alcohol stocks. Both sales and profit margins were under severe pressure, pushing share prices down. Booze consumption, however, is increasing at a slow but steady pace this year, according to data researcher Nielsen. And the rise in consumption is certainly a positive for alcohol stocks.

Innovation and more shake-ups in recent times like Anheuser-Busch InBev SA/NV’s BUD takeover of SABMiller will further help alcohol stocks spiral up this year.

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Things Looking Up for Gaming Companies” data-reactid=”22″>Things Looking Up for Gaming Companies

Robust initiatives helped multi-jurisdictional gaming companies progress by leaps and bounds. But, let’s admit that things are looking up for such companies mostly due to consumer confidence.

Americans are now feeling more optimistic about their present and future conditions. According to the Conference Board, the consumer confidence index climbed to 129.2 in April from 124.2 in March. The key economic indicator that measures attitudes on economic prospects exceeded analysts’ expectations of a 126.9 reading and has rebounded in April after a drop in March.

The future expectations index also moved up to 103 from 98.3. And people’s confidence in present situations improved from 163 in March to 168.3 in April. Both indexes are now close to their highest levels in a decade.

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="5 Sinfully Good Stocks to Buy” data-reactid=”28″>5 Sinfully Good Stocks to Buy

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="As mentioned above, sinful stocks are poised to do much better this year. Such stocks not only celebrate good times but are also useful during recessionary periods. We have selected five such stocks from the pot, alcohol and gaming industries. These stocks possess a Zacks Rank #1 (Strong Buy) or 2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.” data-reactid=”29″>As mentioned above, sinful stocks are poised to do much better this year. Such stocks not only celebrate good times but are also useful during recessionary periods. We have selected five such stocks from the pot, alcohol and gaming industries. These stocks possess a Zacks Rank #1 (Strong Buy) or 2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="GW Pharmaceuticals plc GWPH focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. The cannabinoid drug maker is expected to see an uptick in sales this year, especially, after its lead drug Epidiolex became the first cannabis-derived drug to gain approval from the Food and Drug Administration. The company currently has a Zacks Rank #2. The Zacks Consensus Estimate for its current-year earnings has increased more than 100% over the past 60 days. The stock, which is part of the Medical – Products industry, is expected to see earnings growth of 26.1% in the next quarter.” data-reactid=”30″>GW Pharmaceuticals plc GWPH focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. The cannabinoid drug maker is expected to see an uptick in sales this year, especially, after its lead drug Epidiolex became the first cannabis-derived drug to gain approval from the Food and Drug Administration. The company currently has a Zacks Rank #2. The Zacks Consensus Estimate for its current-year earnings has increased more than 100% over the past 60 days. The stock, which is part of the Medical – Products industry, is expected to see earnings growth of 26.1% in the next quarter.